Kura Oncology/$KURA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Ticker

$KURA
Sector
Primary listing

Employees

192

Kura Oncology Metrics

BasicAdvanced
$831M
-
-$2.26
0.40
-

What the Analysts think about Kura Oncology

Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.

Bulls say / Bears say

FDA’s acceptance of the NDA for ziftomenib with Priority Review and a PDUFA target action date of November 30, 2025, positions Kura one step closer to potential first-in-class approval for R/R NPM1-mutant AML (GlobeNewswire).
Positive data presented at the 2025 ASCO Annual Meeting showed a 23% CR + CRh rate for ziftomenib in the Phase 2 KOMET-001 trial, exceeding historical controls in heavily pretreated R/R NPM1-mutant AML patients (Kura Oncology Q2 Release).
Commercial preparations are advancing with completion of U.S. field sales team hiring and ongoing pre-approval stakeholder engagement, underscoring readiness for launch upon approval (Kura Oncology Q2 Release).
KURA shares hit a 52-week low of $5.65 on April 7, 2025, reflecting persistent investor skepticism despite clinical progress (Investing.com).
Q2 2025 GAAP revenue of $15.3 million missed expectations of $39.1 million, while net loss widened to $66.1 million, highlighting financial pressures before product commercialization (Nasdaq).
JMP Securities cut its price target from $28 to $24 on July 2, 2025, tempering upside expectations amid reassessment of Kura’s clinical-stage pipeline value (Ainvest).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

Kura Oncology Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Kura Oncology Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KURA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs